Valuation dashboard for Immunome, Inc. (IMNM) with P/E N/A, P/B 4.38, EV/EBITDA -8.4 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $20.31 (closing price, November 3, 2026), IMNM has negative trailing earnings (P/E not meaningful) and an ROE of -50.56%. Market capitalisation stands at $2.4B.
Balance sheet quality for IMNM: debt-to-equity ratio of 0.01, current ratio of 15.08 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 4.38 |
| EV / EBITDA | -8.4 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IMNM | Immunome, Inc. | $2.4B | 4.38 | -50.6% | |
| CLDX | Celldex Therapeutics, Inc. | $2.3B | 3.24 | -52.4% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $134.5B | 34.15 | 6.44 | 20.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $100.2B | 21.51 | 2.92 | 15.1% |
| MRNA | Moderna, Inc. | $91.2B | 12.93 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $56.7B | 42.51 | 6.74 | 16.9% |
Price
| Price | $20.31 (closing price, November 3, 2026) |
| Market Cap | $2.4B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -50.56% |
| Return on Invested Capital | -51.06% |
| Return on Assets | -44.98% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLDX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of IMNM: Overview · Financials · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks